These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35793473)

  • 21. Drug Survival of Biologics in Patients With Hidradenitis Suppurativa.
    Ring HC; Maul JT; Yao Y; Wu JJ; Thyssen JP; Thomsen SF; Egeberg A
    JAMA Dermatol; 2022 Feb; 158(2):184-188. PubMed ID: 34851360
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Review of Switching Biologic Agents in the Treatment of Moderate-to-Severe Plaque Psoriasis.
    Hu Y; Chen Z; Gong Y; Shi Y
    Clin Drug Investig; 2018 Mar; 38(3):191-199. PubMed ID: 29249053
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient Preference for Dosing Frequency Based on Prior Biologic Experience.
    Zhang M; Carter C; Olson WH; Johnson MP; Brennem SK; Lee S; Farahi K
    J Drugs Dermatol; 2017 Mar; 16(3):220-226. PubMed ID: 28301617
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association Between Biologics Use and Risk of Serious Infection in Patients With Psoriasis.
    Penso L; Dray-Spira R; Weill A; Pina Vegas L; Zureik M; Sbidian E
    JAMA Dermatol; 2021 Sep; 157(9):1056-1065. PubMed ID: 34287624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics.
    Sator P; Richter L; Saxinger W; Vasiljevic M; Stingl G
    J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1742-9. PubMed ID: 25665143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
    Ross C; Marshman G; Grillo M; Stanford T
    Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.
    Duarte A; Mebrahtu T; Goncalves PS; Harden M; Murphy R; Palmer S; Woolacott N; Rodgers M; Rothery C
    Health Technol Assess; 2017 Nov; 21(64):1-244. PubMed ID: 29105621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biologic drug survival in Israeli psoriasis patients.
    Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
    J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biologics combined with conventional systemic agents for the treatment of children with severe psoriasis. Real-life data from the BiPe cohorts and a practice survey among French and Italian pediatric dermatologists.
    Mahé E; Beauchet A; Hadj-Rabia S; Mazereeuw-Hautier J; Mallet S; Phan A; Severino-Freire M; Boralevi F; Aubert H; Barthélémy H; Girard C; Martin L; Piram M; Barbarot S; Balguerie X; Zitouni J; Phan C; Di Lernia V;
    Dermatol Ther; 2022 Nov; 35(11):e15828. PubMed ID: 36107157
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
    J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.
    Van Muijen ME; Thomas SE; Groenewoud HMM; Otero ME; Ossenkoppele PM; Njoo MD; Dodemont SRP; Kop EN; Berends MAM; Koetsier MIA; Mommers JM; Körver JEM; Tupker RA; De Bruin-Weller MS; Weppner-Parren LJMT; Peters B; Kleinpenning MM; Kuijpers ALA; Arnold WP; Van Lümig PPM; Van den Reek JMPA; De Jong EMGJ
    Acta Derm Venereol; 2022 May; 102():adv00712. PubMed ID: 35356990
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of TNF inhibitors and an IL12/23 inhibitor on changes in body weight and adipokine levels in psoriasis patients: a 48-week comparative study.
    Onsun N; Akaslan TÇ; Sallahoglu K; Gülcan AS; Bulut H; Yabacı A
    J Dermatolog Treat; 2022 May; 33(3):1727-1732. PubMed ID: 33704001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study.
    Zhang M; Goren A; Lee S; DiBonaventura MD; Olson WH
    J Dermatolog Treat; 2016 Aug; 27(4):339-45. PubMed ID: 26558924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
    Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE.
    Klijn SL; van den Reek JMPA; van de Wetering G; van der Kolk A; de Jong EMGJ; Kievit W
    Br J Dermatol; 2018 May; 178(5):1181-1189. PubMed ID: 29247500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching Biologics in the Treatment of Psoriasis: A Multicenter Experience.
    Özkur E; Kıvanç Altunay İ; Oğuz Topal İ; Aytekin S; Topaloğlu Demir F; Özkök Akbulut T; Kara Polat A; Karadağ AS
    Dermatology; 2021; 237(1):22-30. PubMed ID: 31865339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
    Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
    J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A retrospective study on drug survival of biologic among patients with psoriasis seen in tertiary hospital in Johor Malaysia.
    Mashor M; Wong KW; Tey KE; Choon SE
    Med J Malaysia; 2022 Nov; 77(6):689-695. PubMed ID: 36448386
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study.
    Rungapiromnan W; Mason KJ; Lunt M; McElhone K; Burden AD; Rutter MK; Warren RB; Griffiths CEM; Ashcroft DM;
    J Eur Acad Dermatol Venereol; 2020 Apr; 34(4):769-778. PubMed ID: 31633837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.